Tianeptine - Revive Therapeutics

Drug Profile

Tianeptine - Revive Therapeutics

Alternative Names: REV-001; REV-003

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Revive Therapeutics
  • Developer Leiden University; Revive Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action Serotonin uptake stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rett syndrome
  • No development reported Respiratory insufficiency

Most Recent Events

  • 27 Jun 2014 Efficacy and adverse events data from the second part of a phase IIa trial in Respiratory insufficiency released by Revive Therapeutics
  • 14 May 2014 Preclinical trials in Rett syndrome in Canada (unspecified route)
  • 14 May 2014 Pharmacodynamics data from a preclinical study in Rett syndrome released by Revive Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top